Articles On Cynata Therapeutics (ASX:CYP)

Sigma Health says Chemist Warehouse sales gained traction over the last two months Medibank Private also passes the health test Change at the top for medical pot stock   The owner of the monolithic Chemist Warehouse (CW) chain, Sigma Heal...

ASX falls 0.38% with 112/200 stocks (56%) lower Just four sectors on the up; blue-chips drive consumer staples lower Info tech bounces on strong Nasdaq momentum   Info tech rides Nasdaq wave The Wall Street Nasdaq added 0.9% on Friday to...

Firm commitments to raise $1.5m via placement at $0.25 per share Funds to support partnerships and working capital ahead of key trial results Osteoarthritis and aGvHD trial results due May and June 2026   Special Report: Cynata Therapeuti...

Phase III trials are a major catalyst for healthcare companies, mark final proving ground before potential regulatory approval and commercialisation Success can make or break a company with several ASX healthcare names now in the high-stak...

ASX closes lower despite eight sectors finishing in the green Staples smashed as Woolies and Coles sold off sharply Lithium keeps climbing on stronger Chinese futures   It’s eight days straight of S&P/ASX 200 blood. The closing clang...

Aroa shares leap 17% after management flags a full-year earnings beat Impedimed hopes GLP-1 drugs will fatten its profits Little Green hits a European purple patch   Kiwi-based wound care house Aroa Biosurgery (ASX:ARX) has defied the glo...

A gaggle of drug developers is due to disclose company-making clinical study results this year While late-stage clinical trial victory does not confer commercial success, the results tend to be ‘do or die’ In the main, share valuations don...

What are stem cell therapies, when has the technology developed, how is it being advanced, and where is it going? Host Tylah Tully sits down with Cynata Therapeutics (ASX:CYP) managing director and CEO Dr Kilian Kelly to discuss the stem ce...

Morgans healthcare analyst Iain Wilkie highlights seven ASX companies with upcoming catalysts  Dimerix moving into major catalyst window as investors look for further updates from Phase III trial of DMX-200 in FSGS Cynata has results of tw...

ASX lifts from lows of -1.5% to slide -0.65 Energy, utilities, materials, consumer staples make gains Banks and info tech retreat sharply   Aluminium and gold gains limit losses The S&P/ASX 200 had fallen 0.65% by trade’s end, shoved...

100-day primary evaluation period for all 65 participants in Cynata Therapeutics phase II trial of CYP-001 in aGvHD complete The trial’s primary endpoint is overall response rate at day 28, with topline results expected in June 2026 An ear...

A slew of biotechs are raising funds on the back of positive announcements Genetic Signatures wields the scythe in cost-cutting blitz Aroa completes a key trial while Cynata is almost done, too Junior ASX biotechs are successfully raising...

Cynata says Japan’s conditional approval of two induced pluripotent stem cell therapies marks first regulatory validation of technology Company’s Cymerus platform uses induced pluripotent stem cell therapies to generate mesenchymal stem ce...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

Cynata Therapeutics prepares for two advanced clinical trial readouts in Q2 CY26 Company’s Cymerus platform aims to overcome challenges of making efficacious mesenchymal stem cells at scale Results of a phase III osteoarthritis trial and a...

Local life sciences players eyeing developing geographies for potentially higher returns Bioscience Managers talks Türkiye on $145 million fund Adalta’s ‘east meets west’ drug procurement strategy gains traction   As the world’s biggest h...

Rare diseases have become an increasingly attractive target for pharmaceutical companies  Canaccord’s Dr Shane Storey says there are strong incentives for companies to develop therapies for rare diseases Various ASX companies are focusing...

Cynata tackles adult graft-versus-host disease, knee osteoarthritis and kidney disease Having acquired a Perth-based stem-cell program, Neuroscientific targets fistulating Crohn’s disease Following its breakthrough FDA approval, Mesoblast...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

ASX 200 falls 0.72% as global risk-off sentiment hits miners and large caps Copper and iron ore slide, dragging BHP and RioSmall caps buck the trend, with Taruga, EOS and Fortifai posting outsized gains ASX drags its own index down on gove...

Patient enrolment completed in Cynata’s Phase II clinical trial of CYP-001 in acute graft versus host disease Study has enrolled 65 participants in the US, Europe and Australia Primary evaluation period expected to complete in March 2026,...

In a pre-Christmas rush, biotechs report a flurry of clinical activity Radiopharm shares surge up to 22% on strong brain-imaging results Morgans says Sigma Health and EBOS Group shares are just the prescription for the Christmas hamper  ...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Announcement Highlights: Patient enrolment has been completed in Cynata’s Phase 2...

Cynata preparing for two trial readouts in 2026 in knee osteoarthritis and acute graft-versus-host disease  2025 considered a transitional year for stem cell and regenerative medicine company  Cynata’s proprietary Cymerus platform overcome...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX gains 23 points or 0.27% in choppy session of trade Real estate plunges 2.11% while banks and resources make strong gains Bond yields climb to highest level in 2025 on rate hike fears   ASX rides commodity wave higher The ASX 200 adde...

A global study links Alzheimer’s disease with kidney malfunction FDA czar Dr Marty Makary outlines the agency’s priorities Pro Medicus fesses up to a cyber breach   The quest for an Alzheimer’s disease cure has taken a new twist, with an...

Review of first cohort in Cynata’s phase 1/2 NEREID trial in kidney transplant patients successfully completed No safety concerns identified with trial cleared to progress to the next stage Trial managed and funded by global kidney transp...

ASX stumbles as announcement outage leaves traders scrambling to catch up Gold and oil climb, providing some support in energy and resource stocks Wall Street futures weigh heavy; market falls 0.57% ASX scrambles to address announcement b...

ASX powers higher in fresh trading week, up 1.29pc Defensive sectors lead gains with strong support from gold index Energy was the only sector in the red as crude prices fall   Strong start to trading week The ASX 200 has had a strong sta...

Final patient visit completed in Cynata Therapeutics’ Phase III SCUlpTOR trial evaluating CYP-004 in knee osteoarthritis Trial is being conducted by the University of Sydney, which will now finalise quality-control checks before commencin...

Ahead of EBR Systems’ official Wise launch in the US, clinicians already have implanted a dozen patients with the heart device Renerve shares more than double on key US nerve repair military approval   Cynata enters “the most important” ch...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim catches up with Cynata Therapeutics (ASX:CYP) CEO Dr Kilian Kelly to dive into the stem cell ind...

Highlights Duratec and Lovisa identified among undervalued Australian equities. Broader ASX landscape shows resilience amid market diversity. Infrastructure, retail, and technology sectors feature strong value cases. A...

Highlights Undervalued ASX stocks gaining attention across multiple sectors Electro Optic Systems and James Hardie lead the undervaluation list Broader outlook reveals opportunities within the Australian equity landscape...

Highlights Australian market steadies amid global shifts. Emerging undervalued companies gain investor attention. Technology and healthcare sectors lead potential recovery. Australian equities spotlight undervalued opp...

Mesenchymal stromal cells (MSCs) have long been regarded as one of nature’s most powerful repair systems—cells with the ability to reduce inflammation, regulate immune responses and stimulate tissue healing. For decades, they have been seen...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

Neuren’s US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs “with immediate effect”   Despite firming US sales of its Re...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

ASX surges 1.37pc, smashing through record to close at 8757 points All 11 sectors neon green, up between 2.47pc and 0.46pc Healthcare and resources stocks crank higher, leading gains DJ play it louder It was a raver of a party on the ASX...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Highlights Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options. AdAlta, Cynata, and Amplia are advancing innovative therapeutic approaches. Australian biotechnology companies are expanding...

Idiopathic pulmonary fibrosis is a life-threatening lung disease AdAlta’s lead candidate AD-214 is a first-in-class molecule designed to treat IPF Amplia and Cynata therapies also show promise in treating the disease, which has limited tre...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Like London buses, takeovers tend to come in a rush Mayne Pharma had struggled for years, but its performance was improving Takeovers in the ASX biotech sector have been few and far between The ‘London’ Bus theory goes that if one takeove...